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Background: Neurohumoral activation is present in COPD and might provide a link between pulmonary and systemic
effects, especially cardiovascular disease. Because long acting inhaled β-agonists reduce hyperinflation, they could reduce
sympathoexcitation by improving the inflation reflex. We aimed to evaluate if inhaled therapy with salmeterol reduces
muscle sympathetic nerve activity (MSNA) evaluated by microneurography.
Methods: MSNA, heart rate, blood pressure, and respiration were continually measured. After baseline recording of
20 minutes, placebo was administered; after further 45 minutes salmeterol (50 μg) was administered which was followed
by a further 45 minutes of data recording. Additionally, lung function, plasma catecholamine levels, arterial pulse wave
velocity, heart rate variability, and baroreflex sensitivity were evaluated. Following 4 weeks of treatment with salmeterol
50 μg twice daily, measurements were repeated without placebo administration.
Results: A total of 32 COPD patients were included. Valid MSNA signals were obtained from 18 patients. Change in MSNA
(bursts/100 heart beats) following acute administration of salmeterol did not differ significantly from the change following
placebo (-1.96 ± 9.81 vs. -0.65 ± 9.07; p = 0.51) although hyperinflation was significantly reduced. Likewise, no changes in
MSNA or catecholamines were observed after 4 weeks. Heart rate increased significantly by 3.8 ± 4.2 (p < 0.01) acutely and
3.9 ± 4.3 bpm (p < 0.01) after 4 weeks. Salmeterol treatment was safe and well tolerated.
Conclusions: By using microneurography as a gold standard to evaluate sympathetic activity we found no change in
MSNA following salmeterol inhalation. Thus, despite an attenuation of hyperinflation, the long acting β-agonist salmeterol
does not appear to reduce nor incite sympathoexcitation.
Trial registration: This study was registered with the European Clinical Trials Database (EudraCT No. 2011-001581-18) and
ClinicalTrials.gov (NCT01536587).
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Patients with chronic obstructive pulmonary disease
(COPD) are at increased risk of death and disability from
various extra pulmonary complications [1,2]. In COPD
patients, cardiovascular diseases are the most common
comorbidities [3], are one of the leading causes of
hospitalization and one of the main causes of death [4].
It is well known that inhaled β2-agonists induce adverse
effects, such as increased heart rate and tremor [5]. This is* Correspondence: sandreas@lungenfachklinik-immenhausen.de
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creativecommons.org/publicdomain/zero/1.0/thought to be due to spillover of the β-agonist into the
systemic circulation thereby causing direct activation of
β2 and β1 receptors within the cardiovascular system. Fur-
thermore systemic β-agonists (e.g. adrenaline) have excita-
tory effects on the autonomic nervous system such as
direct activation of sympathetic nerve activity [6,7]. Long-
acting β2-agonists (LABA) have an acceptable safety pro-
file, although there is still controversy as to whether LABA
may increase the risk of asthma mortality [8] or new car-
diovascular events in older COPD patients [9].
A striking elevation of sympathetic tone is present in
COPD and might provide a link between COPD and sys-
temic effects, specifically cardiovascular disease [10-14].
Several mechanisms related to lung function impairmentss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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and hyperinflation [17] contribute to sympathetic acti-
vation in COPD [18,19].
In COPD β2-agonists improve lung function, quality
of life and exacerbations [5]. Since these drugs reduce
bronchoconstriction and hyperinflation, it is conceiv-
able that inhaled β2-agonists reduce sympathetic acti-
vation in COPD. Despite their widespread use, the
effects of inhaled β2-agonists on sympathetic activity
have never been investigated.
Previous investigations have demonstrated that
muscle sympathetic nerve activity (MSNA) evaluated
by microneurography reflects short-term changes in
sympathetic activity, is highly reproducible, and corre-
lates closely with cardiac norepinephrine spillover [20],
therefore being considered the gold standard to evalu-
ate sympathetic activity [21].
This study investigates the effects of LABA therapy
on lung function and sympathetic activation in COPD.
The latter involved microneurographic recordings of
MSNA as well as non-invasive assessments of heart rate
variability (HRV), catecholamine levels, and spontan-
eous baroreflexes. Arterial pulse wave velocity (aPWV)
is linked to MSNA, is elevated in COPD and indicates
risk for cardiovascular disease and mortality. Accord-
ingly aPWV was also assessed.
Methods
Study design
This was a partially blinded, single-arm, single centre
study in subjects with COPD GOLD stage II or III. The
study included a screening visit and two study visits
(visit 1 at week 0 and visit 2 at week 4), and one tele-
phone contact at week 2. At the screening visit, eligi-
bility of the subjects was assessed and written
informed consent obtained. At visit 1 a complex meas-
urement period with continuous recordings of MSNA,
blood pressure, tidal volume, respiratory rate, oxygen
saturation and transcutaneous CO2 were conducted
while placebo and 50 μg salmeterol were inhaled by the
subjects in a sequential manner. Following visit 1, all
subjects were treated with salmeterol 50 μg twice daily
for 4 weeks. At visit 2, these observations were re-
peated without placebo inhalation. The subjects were
recruited in a single study centre with the help of two
local chest physicians and newspaper advertisements.
Male or female patients aged between 40 and 80 years
were eligible to enter the study. A prerequisite for in-
clusion was COPD GOLD class II or III with a post-
bronchodilator spirometry forced expiratory volume in
one second (FEV1) <70% predicted, and current or
prior history of ≥10 pack-years of cigarette smoking.
The main exclusion criteria were concomitant active
lung diseases other than COPD, exacerbation orhospitalisation due to COPD six weeks prior to
screening, frequent exacerbations necessitating ther-
apy with inhaled glucocorticosteroids, non-invasive
ventilation, treatment with drugs affecting sympa-
thetic tone (e.g. theophylline), use of systemic gluco-
corticoids or antibiotics, uncontrolled sleep apnoea
syndrome, left heart failure with a left ventricular
ejection fraction <40%, polyneuropathy, or insulin
dependent diabetes mellitus.
The study was performed in a partially blinded man-
ner: The patient was blinded to the sequence of study
drug administration (i.e., to the fact that lactose was
administered as placebo before salmeterol) at visit 1.
Furthermore, the researchers evaluating the recorded
data were blinded to the subject, visit and intervention.
This was done by pseudonymisation of the recorded
data sets of each of the five measurement periods
(baseline, placebo, salmeterol at visit 1; baseline and
salmeterol at visit 2) and removing the time stamps
from each recorded file.Study protocol
Subjects were studied two hours after a low-calorie
meal free from caffeine-containing beverages. They
had been instructed not to smoke any cigarettes for
8 hours before the clinic visit. Study participants were
requested to take their usual medication except for di-
uretics which were to be withheld on the morning of
the study visit. The 2-hour measurement period com-
prised the continuous recording of MSNA, ECG, blood
pressure, respiration, oxygen saturation, and transcuta-
neous CO2 with the patient lying in a supine position.
About 20 minutes after a stable MSNA signal had been
obtained (‘baseline’), one dose of placebo was adminis-
tered; after a further recording period of 45 minutes
one dose of salmeterol (50 μg) was administered which
was followed by a further 45 minutes of data recording.
We analyzed the last 10 minutes of each of these re-
cording sections (baseline, placebo, salmeterol).Muscle sympathetic nerve activity
Sympathetic tone was measured using microneuro-
graphic recordings of efferent muscle sympathetic
nerve activity in the peroneal nerve [22]. A tungsten
microelectrode (shaft diameter 200 μm, tip diameter 1-
5 μm, FHC, Bowdoin, USA) was inserted into the
nerve. The signal was amplified and integrated (662C-
4 Nerve Traffic Analysis System, Absolute Design and
Manufacturing Services, Iowa, USA). Intraobserver
variation in identifying bursts of efferent sympathetic
nerve activity was ~5% in previous studies done in our
laboratory [15,23].
Table 1 Demographic and baseline characteristics
Gender Male, n (%) 21 (65.6)
Female, n (%) 11 (34.4)
Age [years] 61.2 ± 8.4
Body weight [kg] 81.5 ± 19.8
Height [cm] 174.6 ± 7.6
Body mass index [kg/m2] 26.5 ± 5.2
First diagnosis of COPD
[months before screening)
59.0 ± 62.3
GOLD stage II (moderate COPD), n (%) 14 (45.2)
III (severe COPD), n (%) 17 (54.8)
COPD symptoms Breathlessness, n (%) 31 (96.9)
Cough, n (%) 24 (75.0)
Sputum production, n (%) 21 (65.6)
FEV1 [L] 1.6 ± 0.4
FEV1 [% predicted] 50.2 ± 9.9
FVC [L] 2.9 ± 0.8
FEV1/FVC [%] 54.5 ± 9.2
Smoking status Previous smoker, n (%) 13 (40.6)




Pack years 43.1 ± 17.7
COPD = Chronic obstructive pulmonary disease; FEV1 = forced expiratory
volume in one second; FVC = forced vital capacity; GOLD = Global Initiative
for Chronic Obstructive Lung Disease. Values are expressed as mean ± SD
unless otherwise stated.
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variability
ECG (Datex AS/3, Datex Ohmeda, WI, USA) and continu-
ous blood pressure measurements (Portapres, Finapres
Medical Systems, Amsterdam, Netherlands) were used to
obtain data from which heart rate variability (HRV) and
baroreflex sensitivity (BRS) were computed [24,25].
Catecholamine and BNP measurements
During MSNA measurement, blood samples of plasma
norepinephrine, epinephrine and brain natriuretic peptide
(BNP) were taken at least 20 minutes after insertion of an
intravenous line into an antecubital vein at baseline, after
placebo and after salmeterol inhalation.
Lung function, pulse wave velocity, and
echocardiography
Lung function was assessed before and after the MSNA
measurement at visit 1 and visit 2 (at least 60 min. after sal-
meterol inhalation) via body plethysmography and helium
dilution in the sitting position. Carotid-femoral aPWV was
evaluated via SphygmoCor (AT Cor Medical, Itasca, USA)
before MSNA measurement at visit 1 and visit 2.
Transthoracic echocardiography was performed before
visit 1 and visit 2. Because patients need to be completely
relaxed during MSNA recordings, lung function tests,
aPWV and echocardiography could not be performed dur-
ing these measurements.
Sample size calculation
The primary endpoint was the difference in MSNA change
elicited by either salmeterol or placebo inhalation (com-
pared to baseline MSNA levels) on visit 1. According to a
sample size calculation using data from previous studies
(standard deviation of intra-individual difference in MSNA
between 9 and 10 bursts/100 heart beats following inter-
ventions such as oxygen administration or slow breathing
[16,23]), 24 subjects needed to be investigated in order to
be able to detect a 10% difference in MSNA change at a
significance level of 5% and with 80% power. Under the
assumption that adequate microneurographic recordings
would only be obtained in 75% of all subjects studied in
our lab, 32 subjects needed to be enrolled.
Statistical analysis
The statistical analysis was performed using SAS-software,
version 9.2 (SAS institute, Cary, North Carolina, USA).
Data are presented as percentages or means ± standard
deviations, as appropriate. Changes in continuous vari-
ables were assessed using paired t-tests, and Pearson’s co-
efficient was calculated for correlations. The significance
level was set to 5% (two-sided tests). The safety analysis
was based on the analysis of adverse events (AEs).Clinical trial registration
The study was registered with BfArM, the European Clin-
ical Trials Database (EudraCT No. 2011-001581-18) and
www.clinicaltrials.gov (NCT01536587) and approved by
the Ethics Committee of Göttingen University (Applica-
tion number 11/12/11).
More information on the methods of this study is avail-
able as supplementary material (see Additional file 1).
Results
A total of 32 subjects were enrolled. Two subjects discon-
tinued the study prematurely due to an adverse event
(nasopharyngitis and dyspnea; bronchitis).
Demographic and baseline characteristics are summa-
rized in Table 1. Concomitant diseases were reported in
30 subjects (93.8%). Most common were cardiovascular
disorders (17 subjects, 53.1%) with hypertension being the
condition most frequently reported. Concomitant non-
COPD medications were reported in 28 subjects (87.5%).
Most common were anti-thrombotic agents (15 subjects,
46.9%), and medications for cardiovascular disease (14
subjects, 43.8%).
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As calculated on the basis of the residual doses in the
returned dose dispensers 97.5 ± 9.0% of the medication was
used by the patients. Use of rescue medication between
weeks 2 and 4 was reported by 23 subjects (74.2%, N = 31)
at visit 2.Muscle sympathetic nerve activity
A valid MSNA signal for visit 1 was obtained in 18 pa-
tients. In 14 patients a valid MSNA signal could either
not be obtained or was lost in the course of the examin-
ation. Intraobserver variation in identifying bursts was
4.01 ± 0.02%.
Baseline MSNA was 74.4 ± 16.3 bursts/100 heart beats.
This was higher as compared to historical controls [16] of
similar age and BMI. No significant effect of smoking sta-
tus on baseline MSNA was observed (smokers: 75.91 ±
15.44 vs. non-smokers: 71.58 ± 15.20 bursts/100 heart
beats; p = 0.54).
As shown in Figure 1, both placebo and salmeterol in-
halation elicited minor changes in MSNA compared to
baseline levels. The change in MSNA (bursts/100 heartFigure 1 Effects of salmeterol on MSNA, heart rate, systolic and diastolic b
DBP = diastolic blood pressure. * = significant changes in paired t-test (p < 0beats) following acute administration of salmeterol did not
differ significantly from the change following placebo
(-1.96 ± 9.81 vs. -0.65 ± 9.07; p = 0.51). MSNA after salme-
terol inhalation at visit 2 was not significantly different
from MSNA at baseline at visit 1 (change by -3.07 ± 11.59
bursts/100 heart beats; p = 0.38, n = 12).Hemodynamics, baroreflex sensitivity, heart rate
variability, ventilation and pulse wave velocity
Systolic and diastolic blood pressure as well as BRS
showed no relevant changes (Figure 1; Table 2). Heart
rate was significantly increased after acute salmeterol in-
halation at visit 1 and visit 2 as compared to baseline
(Figure 1; Table 2). Resting heart rate after 4 weeks of
salmeterol treatment increased from 65.6 ± 9.4 at base-
line to 67.1 ± 9.9 bpm at visit 2 (before the administra-
tion of salmeterol; p = 0.04 in paired t-test). As an acute
effect of salmeterol, low frequency power (LF) of HRV,
reflecting sympathetic tone, was significantly elevated
while high frequency power (HF), reflecting parasympa-
thetic tone, decreased. There was no correlation between
changes in heart rate, HRV, BRS and changes in MSNA.lood pressure. Displayed are means ± SD. SBP = systolic blood pressure;
.05). For further information see results and Table 2.













Visit 1 (Week 0) Mean ± SD; p (two-sided)
Baseline 65.6 ± 9.4 59.4 ± 38.8 64.5 ± 61.9 53.6 ± 21.8 46.4 ± 21.8 6.3 ± 3.7
After placebo 67.2 ± 9.0 66.9 ± 48.1 75.1 ± 81.6 52.9 ± 22.2 47.1 ± 22.2 6.8 ± 5.9
After salmeterol 69.4 ± 10.1 57.6 ± 33.2 53.0 ± 49.4 62.1 ± 20.3 37.9 ± 20.3 6.2 ± 3.9
Change ‘after
salmeterol’ – Baseline
3.7 ± 4.2; p = <0.01 -1.7 ± 26.4; p = 0.71 -11.5 ± 36.3; p = 0.08 8.4 ± 14.5; p < 0.01 -8.4 ± 14.5; p < 0.01 0.1 ± 1.9; p = 0.84
Visit 2 (Week 4)
Before salmeterol 67.1 ± 9.9 57.0 ± 43.3 55.4 ± 70.4 59.9 ± 19.0 40.1 ± 19.0 7.7 ± 5.1
After salmeterol 69.4 ± 9.4 60.2 ± 48.8 60.8 ± 84.4 55.3 ± 22.8 44.7 ± 22.8 6.5 ± 5.2
Change ‘after
salmeterol’ – Baseline
3.9 ± 4.3; p < 0.01 0.1 ± 53.9; p = 0.99 -5.2 ± 96.1; p = 0.76 2.5 ± 23.3; p = 0.55 -2.5 ± 23.3; p = 0.55 0.2 ± 2.6; p = 0.62
Baseline = value at visit 1 before any inhalation; HF = High frequency component; LF = Low frequency component; SDNN = Standard deviation of the NN interval;
RMSSD = Root mean square of the successive differences.
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ters is shown in Table 3. Mean tidal volume and mean
respiratory minute volume increased after salmeterol in-
halation at visit 1. This effect could not be observed
after 4 weeks of salmeterol treatment. TLC, RV and
FRC significantly decreased after acute and long-term
salmeterol inhalation, while FEV1 was unchanged. Ca-
pillary blood gas analysis (Table 4), continuous mea-
surements of oxygen saturation and transcutaneous
pCO2 revealed no relevant changes.
Echocardiographic data (not shown) and carotid-
femoral aPWV was unchanged after 4 weeks of salme-
terol treatment (9.17 ± 2.06 vs. 8.83 ± 2.23 m/s; p = 0.39).Catecholamine and BNP measurements
The levels of plasma norepinephrine, epinephrine and
brain natriuretic peptide did not change following sal-
meterol inhalation as compared to placebo. However,
there was a significant correlation between changes in
plasma norepinephrine levels and changes in MSNA
after salmeterol administration at visit 2 as compared to
visit 1 (r = 0.72; p = 0.01; Figure 2).Discussion
For the first time the effect of an inhaled β2-agonist on
MSNA was evaluated. The primary endpoint, a signifi-
cant difference in MSNA change following salmeterol
inhalation versus placebo inhalation was not met. How-
ever, MSNA and other measures of neurohumoral acti-
vation such as plasma norepinephrine, BRS and aPWV
did not change following acute or long-term salmeterol
inhalation. These findings are of interest, since previous
work in patients with heart failure indicates that neuro-
humoral activation and sympathoexcitation are linked to
mortality [26-28].Effects on heart rate
Our results showing an increase in heart rate of about 4
beats/minute following inhalation of a sympatho-mimetic
drug corroborate older studies. Cazzola and colleagues
found an increase in heart rate of about 4 beats/minute
with salmeterol in COPD patients with cardiovascular dis-
ease [12]. Blood pressure was not evaluated in that study.
In a recent study using inhaled fluticasone and the long-
acting β2-agonist vilanterol in asthma patients, heart rate
was acutely increased by 3.4 beats/minute. Long-term use
yielded a decrease in heart rate that was greater with pla-
cebo [29]. In COPD patients, the same combination had
no effect on heart rate or blood pressure [30]. Similarly,
the long acting β2-agonist indacaterol at standard doses
had no effect on heart rate or blood pressure in COPD pa-
tients [31]. The fact that salmeterol treatment was associ-
ated with an increase in heart rate without an increase in
MSNA in our study suggests that the increase in heart
rate is caused by activation of cardiac β-receptors rather
than efferent excitatory traffic of the autonomic nervous
system.
Increased resting heart rate is related to mortality in
patients with COPD [32] and heart failure [33]. Salme-
terol as well as other LABA have been successfully used
for inhalation therapy in large studies and for a long
time [34]. In controlled randomised trials, β2-agonists
improve lung function, quality of live and exacerbations
in COPD, but a reduction in mortality was never dem-
onstrated [5]. Interestingly, among older COPD patients,
starting LABA treatment was associated with an in-
creased risk of cardiovascular events in a recent nested
case control analysis [9].
Sympathetic activation
MSNA was increased in our patients and as high or
even higher as compared to previous studies in COPD
Table 3 Lung function and ventilation
FEV1 [L] FVC [L] FRC [L] FRC (helium
dilution) [L]






Visit 1 (Week 0) Mean ± SD; p (two-sided)
Baseline 1.35 ± 0.46 2.60 ± 0.69 4.65 ± 1.33 3.64 ± 0.97 6.61 ± 1.39 3.90 ± 1.28 15.66 ± 3.34 549 ± 200 8362 ± 3333
After salmeterol 1.31 ± 0.40 2.58 ± 0.62 3.86 ± 1.68 3.21 ± 0.78 5.88 ± 1.89 3.16 ± 1.64 15.17 ± 3.45 610 ± 250; 8934 ± 3942




















Visit 2 (Week 4)
Before salmeterol 1.38 ± 0.44 2.68 ± 0.64 4.20 ± 1.61 3.57 ± 0.86 6.23 ± 1.70 3.46 ± 1.61 15.76 ± 3.74 564 ± 197 8773 ± 3369
After salmeterol 1.32 ± 0.46 2.64 ± 0.71 3.67 ± 1.80 3.38 ± 0.77 5.67 ± 1.83 2.90 ± 1.79 15.48 ± 4.02 593 ± 217 8829 ± 3629




































Table 4 Capillary blood gas analysis




Mean ± SD; p (two-sided)
visit 1
(Week 0)
7.43 ± 0.03 92.06 ± 4.79 39.56 ± 3.77 65.69 ± 10.56
visit 2
(Week 4)
7.43 ± 0.03 92.10 ± 4.80 39.26 ± 2.98 65.10 ± 9.83
Change visit









SaO2 = oxygen saturation; pCO2= carbon dioxide tension; pO2 = oxygen tension.
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ous interventional studies using oxygen or slow breath-
ing demonstrated a significant decrease in MSNA
[16,35]. However, in the present study no effect of the
intervention on MSNA was noted. For more insight into
the effects of inhaled β-agonists on sympathetic activity
it is helpful to discuss older work on intravenous ad-
ministration of catecholamines. Adrenaline infusion
(with α1-receptor activity causing vasoconstriction and
β-receptor activity) did cause an increase in MSNA [6].
Intravenous dobutamine (a predominant β1-agonist and
weak β2-agonist without relevant α1 activity) did not
increase MSNA in heart failure patients or matched
controls [36]. While there was no effect on heart rate or
blood pressure in heart failure patients, healthy matched
controls experienced an increase in heart rate but not
blood pressure. In contrast, in an unmatched group of
younger healthy subjects blood pressure increased, and
consecutively MSNA decreased following dobutamineFigure 2 Scatter plot of change in norepinephrine against change in MSNA. D
visit 2 (week 4). (r = 0.72; p = 0.01; n = 11).infusion [36]. In another study intravenous dobutamine
reduced cardiac norepinephrine spillover in patients
with heart failure but not in subjects with normal
ejection fraction [37]. Similarly, in healthy young sub-
jects the increase in heart rate following salmeterol
was explained mainly by a decrease in total peripheral
resistance [38,39]. Our study contributes to the under-
standing of these data by the comprehensive evaluation of
respiration, cardiovascular function and MSNA: In our
older patients with increased sympathetic activity we
did not observe a change in blood pressure or MSNA
following salmeterol.
The observed changes in HRV are suggestive of a de-
crease in parasympathetic tone. Similar results were
observed in a small study using the SABA salbutamol
[38]. However, given the absence of significant changes
in MSNA and baroreflex sensitivity, the HRV findings
are difficult to interpret [40]. Furthermore, changes in
ventilation and heart rate as present in our study im-
pact on HRV thus rendering interpretation even more
problematic.
Sympathoexcitation in COPD is thought to be caused
by several mechanisms such as hypoxia, chemoreflexes
[15], impaired baroreflexes [16] and lung hyperinfla-
tion [17,18]. Lung hyperinflation affects the autonomic
nervous system by activation of intrapulmonary non-
myelinated afferents and by increased end-expiratory
pressure with consecutive impaired left ventricular fill-
ing and reduced stroke volume [17,41,42]. Further-
more hyperinflation increases the work of breathing
[43] and thus impacts on muscle metaboreceptorsisplayed are changes from visit 1 (week 0) to after salmeterol inhalation at
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lung function and hyperinflation following inhaled ther-
apy reduces sympathetic activation. However, despite
reducing hyperinflation, salmeterol did not impact on
sympathetic tone in our study. It is possible that the
positive effects mediated via bronchiodilatation were
too small to elicit a reduction in sympathetic activity.
It is also possible, that any positive effect on sympa-
thetic activity were offset by consequences of systemic
β-receptor activation. Our study is not able to further
dissect these possibilities. In this context it would be
interesting to investigate an inhaled therapy with stronger
bronchodilator activity.
We studied not only the acute but also the long-term
effects of salmeterol over one month. As in the acute
setting, MSNA and other measures of autonomic ner-
vous system activity were unchanged. Desensitization or
saturation of β2-adrenoceptors that follows regular use
of β2-agonist treatment is believed to be responsible for
the resolution of hemodynamic findings after the first
days and weeks and may also prevent long-term effects
of salmeterol on MSNA [5]. However, in our study the
acute effects were comparable to the effects after
4 weeks. Specifically the increase in heart rate was simi-
lar in the acute and long-term setting.Strengths and limitations
In this study, COPD patients underwent a comprehen-
sive protocol including evaluation of the cardiovascular,
respiratory and autonomic nervous system. We used
microneurography as the gold standard to measure
sympathetic activity. The good internal validity of our
data is demonstrated by the positive correlation be-
tween the change in MSNA and the change in plasma
norepinephrine levels. The calculated sample size of 24
patients for the primary endpoint was missed by 6 sub-
jects (n = 18), as we overestimated the rate of successful
MSNA registrations. The per visit success rate of
MSNA recordings is reported as 70% in literature [45].
We had a 56% success rate on visit 1. The difficulty to
keep a stable MSNA signal for a data registration
period of almost two hours was underestimated, as pre-
vious studies [15,16] had distinct shorter registration
periods. As a consequence, the power of the study was
slightly decreased.
Although we implemented a placebo application, no
parallel design was used. Thus we cannot control for
time effects. Nevertheless it is unlikely that the increase
in heart rate with constant MSNA and baroreflexes as
main findings can be explained by the effect of time. A
double blind protocol was not feasible. However,
blinded investigators performed evaluation of MSNA,
heart rate, HRV, BRS, tidal volume and respiratory rate.In our study salmeterol was a weak bronchodilator
because measures of hyperinflation but not FEV1 were
improved. This finding may be explained by the supine
position the patients had to maintain during evaluation
of MSNA and that deep inhalation of the study drug is
difficult in the supine position. Some other studies were
also unable to detect an increase in FEV1 with salme-
terol despite positive findings concerning hyperinflation
or exercise physiology [46].
Conclusions
By using microneurography as a gold standard to evaluate
sympathetic activity we found no change in MSNA follow-
ing acute or chronic salmeterol inhalation. Thus a relevant
negative effect of LABA inhalation on sympathetic activa-
tion is highly unlikely. Further studies with stronger bron-
chodilators are warranted.
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Additional file 1: Supplementary information on the methods of
the study.
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